Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Meningioma × TIC10 compound × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Glioblastoma 2 Endometrial Neoplasms 2 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Meningioma 1 Glioma 1 Fallopian Tube Neoplasms 1 Endometrial Cancer Recurrent 1 Diffuse Intrinsic Pontine Glioma 1 Breast Neoplasms, Male 1

Interventions

Hydroxyurea 7 Everolimus 6 lutetium Lu 177 dotatate 5 Bevacizumab 5 Magnetic Resonance Spectroscopy 4 pembrolizumab 3 abemaciclib 3 Sunitinib 3 Imatinib Mesylate 3 gallium Ga 68 dotatate 2 arginyllysine 2 aldesleukin 2 Whole Body Imaging 2 Specimen Handling 2 Radiotherapy 2 Octreotide 2 Nivolumab 2 Cyclophosphamide 2 Amino Acids 2 90Y-octreotide, DOTA-Tyr(3)- 2 vistusertib 1 vatalanib 1 tozuleristide 1 sargramostim 1 regorafenib 1 pasireotide 1 olaparib 1 neratinib 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡